BRCA2 and pancreatic adenocarcinoma: We report here a 33-year-old Asian woman with extensively metastatic pancreatic adenocarcinoma harboring a germline BRCA2 nonsense mutation who a durable response to fuzuloparib after NALIRIFOX chemotherapy.